Allogene Therapeutics has no cash deposits or securities at Silicon Valley Bank

Allogene Therapeutics, Inc.

Company confirms zero exposure to SVB amid its closure and industry uncertainty.
No cash or securities held at SVB; no financial impact from the bank's collapse.
Disclosure aims to address investor concerns about counterparty risk.

item 7.01

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001737287-23-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.